Document is current
Any future updates will be listed below
-
Authors
Rabelink, Ton J. https://orcid.org/0000-0001-6780-5186
Hosgood, Sarah
Minor, Thomas https://orcid.org/0000-0002-7124-3590
Selzner, Markus https://orcid.org/0000-0002-4326-0887
Weissenbacher, Annemarie https://orcid.org/0000-0002-0582-1815
Leuvenink, Henri GD
Schneeberger, Stefan https://orcid.org/0000-0002-2619-8639
- License Information
-
More Information
Article History
Received: 29 October 2024
Accepted: 21 May 2025
First Online: 25 July 2025
Competing interests
: S.S. has the following disclosures: Grants/Research Support: Chiesi, Neovii, Organ Recovery; Speakers Bureau/Honoraria: Sanofi, OrganOx, Chiesi, Astra Zenica, XVIVO; Consulting Fees: Merck, Atara, NefroHealth, ITB, iCoat Medical, Dialectica, Johnson & Johnson, Sanofi, MSD; None of these represents a conflict of interest, but the interaction with companies in the perfusion industry informed the thinking and the understanding of the field. H.L. is part-time Chief Scientific Officer of 34Lives, PBC, Speakers/consulting honoraria: Neovii, Astra Zenica, NefroHealth. T.R., S.H., T.M., M.S. and A.W. have no competing interests to declare.
